693P - Causes of death in patients with malignant adrenal tumors: A population-based analysis

Background

There is lack of population-based studies to characterize the causes of death for patients with malignant adrenal tumors. Early intervention for these conditions and their correlated risk factors could help prolong survival in these population.

Methods

Data of malignant adrenal tumors patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2020). Based on reference data of the general population, the standardized mortality ratio (SMR) was calculated to assess all causes of death for malignant adrenal tumors patients.

Results

A total of 1651 death cases with malignant adrenal neoplasms were included for further analysis, of which 290 cases were localized disease, 267 cases were regional disease and 1094 patients were metastatic disease. 71.17% cases of death were due to primary malignant adrenal tumors, 15.81% were secondary malignant neoplasms (SMNs), and 13.02% were non-cancer diseases. Main SMNs causes of death included lung and bronchus cancer, soft tissue including heart cancer, and kidney and renal pelvis cancer, while causes of death for non-cancer diseases mainly contained heart diseases, septicemia, and cerebrovascular diseases. Patients who receiving chemotherapy had higher SMR of SMNs including cancers of colon excluding rectum, lung and bronchus, bones and joints, soft tissue including heart, kidney and renal pelvis, brain and other nervous system, and leukemia as well as non-tumor diseases including diseases of heart, septicemia, cerebrovascular diseases than those without chemotherapy. Patients with neuroblastoma were more likely to die as a result of SMNs including lung and bronchus cancers, soft tissue including heart tumors, kidney and renal pelvis cancer, and digestive system tumors.

Conclusions

Other than primary cancer, SMNs and non-tumor diseases are important causes of death in malignant adrenal tumors survivors. Patients with neuroblastoma or those treated by chemotherapy were more likely to die from SMNs and should be paid more attention during their survivorship.

Clinical trial identification

Editorial acknowledgement

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.